Editorial
Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
Abstract
Lung cancer is the leading cause of cancer deaths in the United States and worldwide (1). The majority of patients with newly diagnosed non-small cell lung cancers (NSCLC) have metastasis at presentation but a large group of patients present with locally or regionally advanced disease.